Compare IBRX & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | KRYS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 7.8B |
| IPO Year | 2015 | 2017 |
| Metric | IBRX | KRYS |
|---|---|---|
| Price | $7.94 | $292.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $12.57 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 10.9M | 281.7K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.71 | ★ 128.00 |
| EPS | N/A | ★ 1.83 |
| Revenue | $113,288,000.00 | ★ $389,130,000.00 |
| Revenue This Year | $88.59 | $38.74 |
| Revenue Next Year | $131.15 | $32.53 |
| P/E Ratio | ★ N/A | $167.97 |
| Revenue Growth | ★ 668.31 | 33.94 |
| 52 Week Low | $1.95 | $123.03 |
| 52 Week High | $12.43 | $319.48 |
| Indicator | IBRX | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 54.63 |
| Support Level | $7.77 | $244.43 |
| Resistance Level | $8.51 | $293.60 |
| Average True Range (ATR) | 0.53 | 13.47 |
| MACD | 0.04 | 1.36 |
| Stochastic Oscillator | 62.50 | 61.18 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.